查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2007875

个人化癌症疫苗市场预测至2034年—按疫苗类型、给药途径、技术、应用、最终用户和地区分類的全球分析

Personalized Cancer Vaccines Market Forecasts to 2034 - Global Analysis By Vaccine Type, Delivery Method, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2026 年，全球个人化癌症疫苗市场规模将达到 14 亿美元，并在预测期内以 27.4% 的复合年增长率增长，到 2034 年将达到 98 亿美元。

个人化癌症疫苗是指透过活化患者自体免疫系统，对抗源自于患者自体恶性细胞基因组定序的肿瘤特异性抗原而研发的个人化免疫疗法製剂。这些製剂包括基于新抗原的胜肽製剂、mRNA递送製剂、树突状细胞製剂和DNA疫苗载体。它们透过生物资讯驱动的新抗原预测和快速生产流程製造，用于治疗黑色素瘤、肺癌和其他固体癌患者，以诱导针对患者特异性癌症突变的细胞毒性T细胞反应。

mRNA技术的成熟

mRNA技术的成熟是推动个人化新抗原癌症疫苗规模化、快速生产的变革性动力，而先前这一过程需要数月时间。新冠疫苗计画已证实，脂质奈米颗粒递送系统的优化可直接应用于癌症疫苗製剂，从而缩短生产週期并提高有效载荷稳定性。大型製药企业正在加速投资其个人化mRNA癌症疫苗研发管线，建构后期临床资产组合，并验证其商业化路径的可行性。

製造复杂性和成本

生产过程的复杂性和每位患者高昂的生产成本限制了个人化癌症疫苗的普及。每种疫苗都需要在临床可接受的时限内进行个别基因组定序、新抗原优先排序以及客製化胜肽或mRNA合成。对先进的GMP生物製造基础设施和高技能人员的需求显着增加了固定成本。这些障碍对缺乏癌症治疗预算柔软性的医疗系统而言尤其不利，使得目前的商业性可行性仅限于高端市场。

联合免疫疗法通讯协定

将个人化癌症疫苗与查核点抑制剂结合的联合免疫疗法通讯协定展现出巨大的发展潜力，因为越来越多的临床证据表明，其协同肿瘤缓解率高于任何单一疗法。肿瘤科医师和保险公司也越来越接受组合方案，只要其持续疗效能够抵销成本。监管机构正在简化肿瘤联合治疗的快速核准流程，为个人化疫苗研发商与成熟的查核点抑制剂生产商合作，以加速产品商业化进程铺路。

查核点抑制剂的竞争格局

已通过核准的查核点抑制剂的竞争格局已然形成，这对个人化癌症疫苗的市场推广构成了重大威胁。这是因为肿瘤科医师依赖那些疗效成熟、医保报销机製完善且被纳入临床指引的药物。要在大型临床试验中证明其疗效优于现有标准疗法，需要大量投资，并面临巨大的监管风险。患者和医生对实验性个人化疗法作为成熟治疗方法替代方案的抵触情绪，进一步限制了其在临床试验框架之外的短期应用。

新冠疫情的影响：

新冠疫情大大加速了个人化癌症疫苗的研发，因为它展示了mRNA递送平台和脂质奈米颗粒的大规模生产。疫情期间，疫苗技术开发人员和肿瘤学专家之间的合作创造了技术转移的机会，并缩短了研发週期。疫情后，监管机构推出了适用于个人化癌症疗法的简化版、适应性强的临床试验指南，为研发管线带来了结构性优势。

在预测期内，DNA疫苗细分市场预计将成为最大的细分市场。

由于DNA疫苗相比mRNA疫苗具有更优异的稳定性、成熟的生产过程以及在黑色素瘤和肺癌等适应症领域不断拓展的后期临床试验管线，预计在预测期内，DNA疫苗将占据最大的市场份额。 DNA疫苗无需低温储存，提高了在不同临床环境中的物流可行性。多项评估个人化DNA疫苗平台合併查核点抑制剂的III期临床试验正在产生积极的中期数据，为商业性前景提供了有力支撑。

预计基因测序领域在预测期内将呈现最高的复合年增长率。

在预测期内，基因组定序领域预计将呈现最高的成长率，这主要得益于全EXOME显子定序成本的快速下降以及主要医疗系统临床基因组学基础设施的扩展。随着美国和欧洲保险覆盖范围的扩大，基因组定序在肿瘤分析中的实用化正在加速发展。将次世代定序工作流程直接整合到医院肿瘤科的诊疗流程中，使得新抗原数据成为个人化疫苗生产流程中不可或缺的关键资讯。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这得益于其先进的临床试验基础设施、在个性化肿瘤学领域主导的生物製药投资，以及包括FDA突破性疗法和加速核准在内的有利法规环境。美国拥有大多数处于后期阶段的个人化癌症疫苗临床计画。高昂的抗癌药物支出和基因组分析的健保覆盖，为已通过核准的个人化疫苗产品早期进入市场创造了有利的商业性条件。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于癌症患者数量的快速增长、各国政府对基因组医疗基础设施的投资，以及中国、日本和韩国临床试验活动的不断扩大。亚太地区主要经济体的国家癌症控制计画正在将基因组肿瘤分析纳入标准诊断流程。日本和中国对创新肿瘤生技药品的快速监管核准流程，正加速个人化疫苗开发商进入市场。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，我们可以提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需要进行可行性测试）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 成长动力、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章：全球个人化癌症疫苗市场：依疫苗类型划分

  • 基于新抗原的疫苗
  • 树突细胞疫苗
  • 基于mRNA的疫苗
  • 基于胜肽的疫苗
  • DNA疫苗
  • 癌细胞疫苗
  • 其他疫苗类型

第六章：全球个人化癌症疫苗市场：依给药途径划分

  • 静脉注射
  • 皮下
  • 皮内注射
  • 肌肉内部
  • 奈米颗粒递送
  • 脂质奈米颗粒

第七章：全球个人化癌症疫苗市场：依技术划分

  • 基因组定序
  • 次世代定序（NGS）
  • 生物资讯平台
  • 免疫资讯学
  • 人工智慧驱动的疫苗设计
  • 单细胞分析

第八章：全球个人化癌症疫苗市场：按应用领域划分

  • 黑色素瘤
  • 肺癌
  • 乳癌
  • 摄护腺癌
  • 结肠癌
  • 骨髓恶性肿瘤
  • 其他用途

第九章：全球个人化癌症疫苗市场：依最终用户划分

  • 医院
  • 肿瘤诊所
  • 研究机构
  • 生技公司
  • 製药公司
  • 临床试验中心
  • 其他最终用户

第十章：全球个人化癌症疫苗市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟、合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Moderna Inc.
  • BioNTech SE
  • Gritstone bio, Inc.
  • CureVac NV
  • Roche Holding AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Novartis AG
  • Sanofi SA
  • Genentech Inc.
  • Immatics NV
  • ISA Pharmaceuticals
  • Neon Therapeutics
  • Nouscom AG
  • Transgene SA
  • Adaptimmune Therapeutics
Product Code: SMRC34761

According to Stratistics MRC, the Global Personalized Cancer Vaccines Market is accounted for $1.4 billion in 2026 and is expected to reach $9.8 billion by 2034 growing at a CAGR of 27.4% during the forecast period. Personalized cancer vaccines refer to individualized immunotherapeutic constructs designed to prime the patient's immune system against tumor-specific antigens derived from genomic sequencing of their own malignant cells. They encompass neoantigen-based peptide formulations, mRNA delivery constructs, dendritic cell preparations, and DNA vaccine vectors. Manufactured through bioinformatics-driven neoantigen prediction and rapid manufacturing workflows, they are administered to melanoma, lung cancer, and other solid tumor patients, stimulating cytotoxic T-cell responses against patient-specific cancer mutations.

Market Dynamics:

Driver:

mRNA Technology Maturation

mRNA technology maturation is a transformative driver enabling scalable, rapid manufacturing of personalized neoantigen cancer vaccines that previously required months of production. Lipid nanoparticle delivery optimization validated through COVID-19 vaccine programs has directly transferred to oncology vaccine formulation, reducing manufacturing cycle times and improving payload stability. Major pharmaceutical entities are accelerating personalized mRNA cancer vaccine pipeline investments, generating late-stage clinical asset portfolios and substantiating commercial pathway feasibility.

Restraint:

Manufacturing Complexity and Cost

Manufacturing complexity and prohibitive per-patient production costs constrain personalized cancer vaccine accessibility, as each vaccine requires individual genomic sequencing, neoantigen prioritization, and bespoke peptide or mRNA synthesis within clinically meaningful timeframes. Sophisticated GMP biomanufacturing infrastructure and highly skilled personnel requirements elevate fixed costs substantially. These barriers disproportionately restrict access in healthcare systems with limited oncology drug budget flexibility, confining current commercial viability to premium market segments.

Opportunity:

Combination Immunotherapy Protocols

Combination immunotherapy protocols integrating personalized cancer vaccines with checkpoint inhibitors present a major opportunity, as clinical evidence increasingly demonstrates synergistic tumor response rates exceeding either modality alone. Oncology physicians and payers are showing growing acceptance of combination regimens where response durability justifies combined costs. Regulatory agencies are streamlining accelerated approval frameworks for combination oncology approaches, creating faster commercial pathways for personalized vaccine developers partnering with established checkpoint inhibitor manufacturers.

Threat:

Competitive Checkpoint Inhibitor Landscape

The entrenched competitive landscape of approved checkpoint inhibitors represents a significant threat to personalized cancer vaccine commercial adoption, as oncologists rely on well-characterized agents with established reimbursement and clinical guideline inclusion. Demonstrating superior efficacy versus existing standard of care in pivotal trials requires substantial investment and carries meaningful regulatory risk. Patient and physician resistance to experimental personalized approaches in lieu of proven therapies further constrains near-term uptake beyond clinical trial settings.

Covid-19 Impact:

COVID-19 profoundly accelerated personalized cancer vaccine development by validating mRNA delivery platforms and lipid nanoparticle manufacturing at scale. Pandemic-era partnerships between vaccine technology developers and oncology specialists created technology transfer opportunities that compressed development timelines. Post-pandemic, regulatory agencies introduced streamlined adaptive trial guidance applicable to personalized oncology therapeutics, structurally benefiting the pipeline.

The DNA-based vaccines segment is expected to be the largest during the forecast period

The DNA-based Vaccines segment is expected to account for the largest market share during the forecast period, due to their stability advantages over mRNA constructs, established manufacturing processes, and growing late-stage clinical pipeline across melanoma and lung cancer indications. DNA vaccines do not require ultra-cold storage, improving logistical feasibility for diverse clinical settings. Multiple Phase III trials evaluating personalized DNA vaccine platforms in combination with checkpoint inhibitors are generating positive interim data supporting commercial expectations.

The genomic sequencing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Genomic Sequencing segment is predicted to witness the highest growth rate, driven by rapidly declining whole-exome sequencing costs and expanding clinical genomics infrastructure in major healthcare systems. Real-world genomic sequencing adoption for tumor profiling is accelerating as reimbursement coverage expands in the U.S. and Europe. The integration of next-generation sequencing workflows directly into hospital oncology pathways is generating the neoantigen data inputs essential for personalized vaccine manufacturing pipelines.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to advanced clinical trial infrastructure, leading biopharmaceutical investment in personalized oncology, and supportive regulatory environments including FDA breakthrough therapy and accelerated approval designations. The United States hosts the majority of late-stage personalized cancer vaccine clinical programs. High oncology drug expenditure and insurance coverage for genomic profiling create commercial conditions supporting early market penetration for approved personalized vaccine products.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly expanding oncology patient populations, government investments in genomic medicine infrastructure, and growing clinical trial activity across China, Japan, and South Korea. National cancer control programs in major Asia Pacific economies are integrating genomic tumor profiling into standard diagnostic workflows. Accelerated regulatory approval pathways for innovative oncology biologics in Japan and China are facilitating faster market entry for personalized vaccine developers.

Key players in the market

Some of the key players in Personalized Cancer Vaccines Market include Moderna Inc., BioNTech SE, Gritstone bio, Inc., CureVac N.V., Roche Holding AG, Merck & Co., Inc., Pfizer Inc., AstraZeneca plc, GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Genentech Inc., Immatics N.V., ISA Pharmaceuticals, Neon Therapeutics, Nouscom AG, Transgene SA, and Adaptimmune Therapeutics.

Key Developments:

In March 2026, Moderna Inc. announced expansion of its personalized cancer vaccine manufacturing capacity through a new U.S.-based GMP production facility partnership.

In February 2026, Roche Holding AG entered a co-development agreement to evaluate personalized neoantigen vaccine combination regimens with atezolizumab across multiple solid tumor types.

In January 2026, BioNTech SE reported positive Phase II data for its individualized neoantigen mRNA cancer vaccine combined with pembrolizumab in advanced melanoma patients.

In October 2025, Gritstone bio, Inc. initiated a Phase II clinical trial evaluating its GRANITE neoantigen cancer vaccine in combination with checkpoint immunotherapy for colorectal cancer.

Vaccine Types Covered:

  • Neoantigen-based Vaccines
  • Dendritic Cell Vaccines
  • mRNA-based Vaccines
  • Peptide-based Vaccines
  • DNA-based Vaccines
  • Tumor Cell Vaccines
  • Other Vaccine Types

Delivery Methods Covered:

  • Intravenous
  • Subcutaneous
  • Intradermal
  • Intramuscular
  • Nanoparticle Delivery
  • Lipid Nanoparticles

Technologies Covered:

  • Genomic Sequencing
  • Next-Generation Sequencing (NGS)
  • Bioinformatics Platforms
  • Immunoinformatics
  • AI-driven Vaccine Design
  • Single-cell Analysis

Applications Covered:

  • Melanoma
  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Hematological Malignancies
  • Other Applications

End Users Covered:

  • Hospitals
  • Oncology Clinics
  • Research Institutes
  • Biotech Companies
  • Pharma Companies
  • Clinical Trial Centers
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Cancer Vaccines Market, By Vaccine Type

  • 5.1 Neoantigen-based Vaccines
  • 5.2 Dendritic Cell Vaccines
  • 5.3 mRNA-based Vaccines
  • 5.4 Peptide-based Vaccines
  • 5.5 DNA-based Vaccines
  • 5.6 Tumor Cell Vaccines
  • 5.7 Other Vaccine Types

6 Global Personalized Cancer Vaccines Market, By Delivery Method

  • 6.1 Intravenous
  • 6.2 Subcutaneous
  • 6.3 Intradermal
  • 6.4 Intramuscular
  • 6.5 Nanoparticle Delivery
  • 6.6 Lipid Nanoparticles

7 Global Personalized Cancer Vaccines Market, By Technology

  • 7.1 Genomic Sequencing
  • 7.2 Next-Generation Sequencing (NGS)
  • 7.3 Bioinformatics Platforms
  • 7.4 Immunoinformatics
  • 7.5 AI-driven Vaccine Design
  • 7.6 Single-cell Analysis

8 Global Personalized Cancer Vaccines Market, By Application

  • 8.1 Melanoma
  • 8.2 Lung Cancer
  • 8.3 Breast Cancer
  • 8.4 Prostate Cancer
  • 8.5 Colorectal Cancer
  • 8.6 Hematological Malignancies
  • 8.7 Other Applications

9 Global Personalized Cancer Vaccines Market, By End User

  • 9.1 Hospitals
  • 9.2 Oncology Clinics
  • 9.3 Research Institutes
  • 9.4 Biotech Companies
  • 9.5 Pharma Companies
  • 9.6 Clinical Trial Centers
  • 9.7 Other End Users

10 Global Personalized Cancer Vaccines Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Moderna Inc.
  • 13.2 BioNTech SE
  • 13.3 Gritstone bio, Inc.
  • 13.4 CureVac N.V.
  • 13.5 Roche Holding AG
  • 13.6 Merck & Co., Inc.
  • 13.7 Pfizer Inc.
  • 13.8 AstraZeneca plc
  • 13.9 GlaxoSmithKline plc
  • 13.10 Novartis AG
  • 13.11 Sanofi S.A.
  • 13.12 Genentech Inc.
  • 13.13 Immatics N.V.
  • 13.14 ISA Pharmaceuticals
  • 13.15 Neon Therapeutics
  • 13.16 Nouscom AG
  • 13.17 Transgene SA
  • 13.18 Adaptimmune Therapeutics

List of Tables

  • Table 1 Global Personalized Cancer Vaccines Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Personalized Cancer Vaccines Market Outlook, By Vaccine Type (2023-2034)($MN)
  • Table 3 Global Personalized Cancer Vaccines Market Outlook, By Neoantigen-based Vaccines (2023-2034)($MN)
  • Table 4 Global Personalized Cancer Vaccines Market Outlook, By Dendritic Cell Vaccines (2023-2034)($MN)
  • Table 5 Global Personalized Cancer Vaccines Market Outlook, By mRNA-based Vaccines (2023-2034)($MN)
  • Table 6 Global Personalized Cancer Vaccines Market Outlook, By Peptide-based Vaccines (2023-2034)($MN)
  • Table 7 Global Personalized Cancer Vaccines Market Outlook, By DNA-based Vaccines (2023-2034)($MN)
  • Table 8 Global Personalized Cancer Vaccines Market Outlook, By Tumor Cell Vaccines (2023-2034)($MN)
  • Table 9 Global Personalized Cancer Vaccines Market Outlook, By Other Vaccine Types (2023-2034)($MN)
  • Table 10 Global Personalized Cancer Vaccines Market Outlook, By Delivery Method (2023-2034)($MN)
  • Table 11 Global Personalized Cancer Vaccines Market Outlook, By Intravenous (2023-2034)($MN)
  • Table 12 Global Personalized Cancer Vaccines Market Outlook, By Subcutaneous (2023-2034)($MN)
  • Table 13 Global Personalized Cancer Vaccines Market Outlook, By Intradermal (2023-2034)($MN)
  • Table 14 Global Personalized Cancer Vaccines Market Outlook, By Intramuscular (2023-2034)($MN)
  • Table 15 Global Personalized Cancer Vaccines Market Outlook, By Nanoparticle Delivery (2023-2034)($MN)
  • Table 16 Global Personalized Cancer Vaccines Market Outlook, By Lipid Nanoparticles (2023-2034)($MN)
  • Table 17 Global Personalized Cancer Vaccines Market Outlook, By Technology (2023-2034)($MN)
  • Table 18 Global Personalized Cancer Vaccines Market Outlook, By Genomic Sequencing (2023-2034)($MN)
  • Table 19 Global Personalized Cancer Vaccines Market Outlook, By Next-Generation Sequencing (NGS) (2023-2034)($MN)
  • Table 20 Global Personalized Cancer Vaccines Market Outlook, By Bioinformatics Platforms (2023-2034)($MN)
  • Table 21 Global Personalized Cancer Vaccines Market Outlook, By Immunoinformatics (2023-2034)($MN)
  • Table 22 Global Personalized Cancer Vaccines Market Outlook, By AI-driven Vaccine Design (2023-2034)($MN)
  • Table 23 Global Personalized Cancer Vaccines Market Outlook, By Single-cell Analysis (2023-2034)($MN)
  • Table 24 Global Personalized Cancer Vaccines Market Outlook, By Application (2023-2034)($MN)
  • Table 25 Global Personalized Cancer Vaccines Market Outlook, By Melanoma (2023-2034)($MN)
  • Table 26 Global Personalized Cancer Vaccines Market Outlook, By Lung Cancer (2023-2034)($MN)
  • Table 27 Global Personalized Cancer Vaccines Market Outlook, By Breast Cancer (2023-2034)($MN)
  • Table 28 Global Personalized Cancer Vaccines Market Outlook, By Prostate Cancer (2023-2034)($MN)
  • Table 29 Global Personalized Cancer Vaccines Market Outlook, By Colorectal Cancer (2023-2034)($MN)
  • Table 30 Global Personalized Cancer Vaccines Market Outlook, By Hematological Malignancies (2023-2034)($MN)
  • Table 31 Global Personalized Cancer Vaccines Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 32 Global Personalized Cancer Vaccines Market Outlook, By End User (2023-2034)($MN)
  • Table 33 Global Personalized Cancer Vaccines Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 34 Global Personalized Cancer Vaccines Market Outlook, By Oncology Clinics (2023-2034)($MN)
  • Table 35 Global Personalized Cancer Vaccines Market Outlook, By Research Institutes (2023-2034)($MN)
  • Table 36 Global Personalized Cancer Vaccines Market Outlook, By Biotech Companies (2023-2034)($MN)
  • Table 37 Global Personalized Cancer Vaccines Market Outlook, By Pharma Companies (2023-2034)($MN)
  • Table 38 Global Personalized Cancer Vaccines Market Outlook, By Clinical Trial Centers (2023-2034)($MN)
  • Table 39 Global Personalized Cancer Vaccines Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.